Advertisement

Supply Chain



As President-elect Donald Trump prepares to take office with a Republican-controlled Congress, major shifts in drug pricing policies are not expected, a new report by investment research firm Morningstar claims. However, the firm suggests ACA changes would likely focus on…

Amid controversial price hikes and surprising regulatory decisions, many aspects of the drug industry were scrutinized this past year.

Advertisement